CEO of Axogen Sells More Than $300,000 in Company Shares, According to

Table of contents

CEO of Axogen Sells More Than 0,000 in Company Shares, According to

© Reuters.

Axogen, Inc. (NASDAQ: AXGN) CEO Karen L. Zaderej recently engaged in transactions involving the company’s common stock, according to a new SEC filing. On March 21, Zaderej sold a total of 36,280 shares of Axogen at a price of $7.68 per share, generating proceeds of $301,670.

The transactions took place shortly after Zaderej acquired a significant number of restricted stock units (RSUs) on March 16. The acquisition of these RSUs increased its common stock ownership, which was followed by the sale of stock to cover tax withholding obligations as required by law. requirements of the company’s stock incentive plan. These sales constitute a mandatory part of the acquisition process and are not considered discretionary transactions by the reporting person.

The recent filing indicates that after these transactions, Zaderej still owns a significant number of shares of Axogen, with his ownership totaling 1,143,788 shares after the sales. This movement of stocks is part of the regular financial activities of managers, as highlighted by share incentive plans and the associated tax implications.

Investors and market observers often look to these documents for insight into executives’ confidence in the company’s future performance, although such sales are frequently planned and can be a routine part of personal financial management. leaders.

Axogen, Inc. specializes in the development and commercialization of technologies for the regeneration and repair of peripheral nerves, a critical area of ​​medical science that addresses the need for improved surgical solutions for nerve injuries. The company’s stock performance and executive trading are closely watched by investors seeking to understand the company’s health and strategic direction.

InvestingPro Insights

As Axogen, Inc. (NASDAQ: AXGN) navigates through the challenges and opportunities of the peripheral nerve regeneration and repair market, its financial health and stock performance remain critical to investors. According to InvestingPro data, Axogen currently has a market capitalization of approximately $320.59 million. Despite notable revenue growth of 14.74% over the trailing twelve months to Q4 2023, Axogen’s profitability is under scrutiny, with a reported operating margin of -13.5% for the same period. These numbers are essential to understanding the company’s financial position and its potential for future growth.

An InvestingPro tip points out that Axogen stock is currently considered to be in oversold territory based on the relative strength index (RSI), which could be of interest to potential investors looking for entry points. Additionally, the company’s liquidity exceeds its short-term obligations, indicating some degree of short-term financial stability. It is worth noting, however, that analysts have lowered their earnings expectations for the coming period and do not expect the company to be profitable this year.

For those tracking stock performance, Axogen shares have seen a significant rise over the past six months, with a total return of 58.55%. Yet the one-month total price return saw a decline of 29.0%, reflecting the stock’s recent volatility. Investors may find these metrics helpful when thinking about when they make their investment decisions. For more in-depth analysis of Axogen’s financial and stock data, including additional InvestingPro advice, visit There are currently 9 additional tips available on InvestProand using the promo code PRONEWS24readers can get an additional 10% off an annual or bi-annual Pro and Pro+ subscription.

This article was generated with the support of AI and reviewed by an editor. For more information, consult our General Terms and Conditions.

Source Reference

Latest stories